At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 994 enrolled
Drug / intervention
Abatacept +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3B, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination With Methotrexate Compared to Methotrexate Monotherapy in Achieving Clinical Remission in Adults With Early Rheumatoid Arthritis Who Are Methotrexate Naive
In Brief
A Phase 3 clinical trial evaluating Abatacept, Methotrexate, and 2 other interventions for Rheumatoid Arthritis. Completed, enrolled 994 participants across 201 sites in 31 countries.
Detailed Summary
The purpose of this study is to determine if abatacept is effective in the treatment of early rheumatoid arthritis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesArgentina, Australia, Austria, Brazil, Canada, Chile, Colombia, Czechia, Finland, France, Germany, Hungary, Israel, Italy, Japan, Mexico, Monaco, Netherlands, Peru, Poland, Qatar, Romania, Russia, Singapore, South Africa, South Korea, Spain, Sweden, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 2015
Enrollment StartSep 2015
Primary CompletionJan 2017
Study CompletionMar 2020
TodayJul 2026
First PostedJul 21, 2015
Enrollment StartSep 3, 2015
Primary CompletionJan 16, 2017
Study CompletionMar 19, 2020
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 10.9 years ago
Interventions
Abataceptdrug
Methotrexatedrug
Abatacept Placeboother
Methotrexate Placeboother